Connect with us

Edronax (reboxetine)

Reboxetine (or EDRONAX, PROLIFT®) is mainly prescribed to treat unipolar depression, panic disorder, and attention deficit hyperactivity disorder.

Status: ACTIVE

Class: Norepinephrine Reuptake Inhibitor (NRI)

FDA Approval: 1999; International Only (AU, IE, IL, NZ, ZA, UK, AR, BR, CL, VE)

Dosage Forms: 2 mg, 4 mg

Biological Half-life: 12-12.5 hours

Side Effects: Dizziness, dry mouth, constipation, agitation, anxiety, insomnia, urinary retention, sexual dysfunction, hypotension

Routes of Administration: Oral

Pregnancy Category: B1 (AU)


Twitter Feed

Gene discovery may explain why Lithium doesn't work for all patients

Researchers found insomnia may increase risk of mood disorder in teens #mentalhealth @PittTweet

Can Tylenol provide relief for social media anxiety? #FOMO #socialanxiety #cyberpsychology